ARQT - Bristol Myers announces positive data for deucravacitinib in plaque psoriasis

Bristol Myers Squibb (BMY) is up ~1.6% in premarket after the company announced positive topline results from a pivotal Phase 3 trial evaluating deucravacitinib for the treatment of moderate to severe plaque psoriasis.POETYK PSO-2, the second of two global Phase 3 studies, has evaluated 6mg once-daily deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor.The study has met both co-primary endpoints versus placebo and multiple key secondary endpoints. The company expects to share the detailed results after a full evaluation of OETYK PSO-2 data in the future.Co-primary endpoints:Significantly more patients have achieved Psoriasis Area and Severity Index (PASI 75), defined as at least a 75 percent improvement of baseline PASI and a static Physician's Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.Key secondary endpoints:The treatment was superior to Otezla® (apremilast) in the proportion of patients reaching PASI 75 and sPGA 0/1 at Week 16.Safety profile:Consistent

For further details see:

Bristol Myers announces positive data for deucravacitinib in plaque psoriasis